[{"Assets_0_Q2_USD":640024000.0,"CommonStockSharesOutstanding_0_Q2_shares":21049741.0,"EarningsPerShareBasic_1_Q2_USD":0.29,"EarningsPerShareBasic_2_Q2_USD":0.53,"EarningsPerShareDiluted_1_Q2_USD":0.26,"EarningsPerShareDiluted_2_Q2_USD":0.48,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":34608000.0,"NetIncomeLoss_1_Q2_USD":6058000.0,"NetIncomeLoss_2_Q2_USD":11137000.0,"StockholdersEquity_0_Q2_USD":385116000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":23215900.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":23117164.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":21013000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":20975000.0,"Ticker":"LGND","CIK":"886163","name":"LIGAND PHARMACEUTICALS INC","OfficialName":"Ligand Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1738856427.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170809"}]